keyword
MENU ▼
Read by QxMD icon Read
search

Pustular psoriasis

keyword
https://www.readbyqxmd.com/read/27904292/a-case-of-acrodermatitis-continua-accompanying-with-osteolysis-and-atrophy-of-the-distal-phalanx-that-evoluted-into-generalized-pustular-psoriasis
#1
Kyung Ho Kim, Hong Lim Kim, Hyun Yi Suh, Jae Wook Jeon, Ji Young Ahn, Mi Youn Park, Jai Il Youn
No abstract text is available yet for this article.
December 2016: Annals of Dermatology
https://www.readbyqxmd.com/read/27900482/mutations-in-il36rn-are-associated-with-geographic-tongue
#2
Jianying Liang, Peichen Huang, Huaguo Li, Jia Zhang, Cheng Ni, Yirong Wang, Jinwen Shen, Chunxiao Li, Lu Kang, Jie Chen, Hui Zhang, Zhen Wang, Zhen Zhang, Ming Li, Zhirong Yao
Geographic tongue (GT) is a benign inflammatory disorder of unknown etiology. Epidemiology and histopathology in previous studies found that generalized pustular psoriasis (GPP) is a factor associated with GT, but the molecular mechanism remains obscure. To investigate the mechanism of GT, with and without GPP, three cohorts were recruited to conduct genotyping of IL36RN, which is the causative gene of GPP. In a family spanning three generations and diagnosed with only GT ("GT alone"), GT was caused by the c...
November 29, 2016: Human Genetics
https://www.readbyqxmd.com/read/27884600/steaps-comprise-a-novel-inflammatory-nexus-in-pustular-skin-disorders
#3
Yun Liang, Xianying Xing, Maria A Beamer, William R Swindell, Mrinal K Sarkar, Liza Wolterink Roberts, John J Voorhees, J Michelle Kahlenberg, Paul W Harms, Andrew Johnston, Johann E Gudjonsson
BACKGROUND: Pustular skin disorders are a category of difficult-to-treat and potentially life threatening conditions that involve the appearance of neutrophil rich pustules. The molecular basis of most pustular skin conditions has remained unknown. OBJECTIVE: We sought to investigate the molecular basis of three pustular skin disorders, generalized pustular psoriasis (GPP), palmoplantar pustulosis (PPP), and acute generalized exanthematous pustulosis (AGEP). METHODS: Microarray analyses were performed to profile genome-wide gene expression of skin biopsies obtained from GPP, PPP, AGEP patients and normal controls...
November 21, 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27882586/efficacy-and-safety-of-dose-escalation-of-infliximab-therapy-in-japanese-patients-with-psoriasis-results-of-the-spread-study
#4
Hideshi Torii, Masayuki Nakano, Toshiro Yano, Kazuoki Kondo, Hidemi Nakagawa
Although infliximab is approved for psoriasis, its efficacy is reduced over time in some patients. The aim of this phase III trial is to evaluate efficacy and safety of infliximab dose escalation in Japanese psoriasis patients with loss of efficacy to standard-dose therapy. Patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis or psoriatic erythroderma who showed loss of efficacy to standard-dose therapy received infliximab dose escalation (10 mg/kg every 8 weeks) from weeks 0 to 32. Loss of efficacy was defined as not maintaining 50% reduction in the Psoriasis Area and Severity Index (PASI 50) after achieving PASI 75...
November 24, 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/27881938/are-interleukin-15-and-22-a-new-pathogenic-factor-in-pustular-palmoplantar-psoriasis
#5
Aleksandra Lesiak, Igor Bednarski, Marta Pałczyńska, Ewelina Kumiszcza, Marzena Kraska-Gacka, Anna Woźniacka, Joanna Narbutt
INTRODUCTION: Pustular palmoplantar psoriasis (PPP) is a rare type of psoriasis affecting mainly distal parts of the limbs. Despite numerous theories about etiology of PPP, the pathogenesis still remains unclear. Recent data indicate that interleukin (IL)-15, IL-17 and IL-22 enhance a proinflammatory response in certain skin inflammatory diseases such as psoriasis and atopic dermatitis. There is also evidence that anti-endomysial (anti-EMA) and anti-gliadin (AGA) antibodies are engaged in PPP development...
October 2016: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/27879067/ustekinumab-in-the-treatment-of-palmoplantar-pustular-psoriasis-a-case-series-of-nine-patients
#6
Valeska Buder, Katharina Herberger, Arnd Jacobi, Matthias Augustin, Marc Alexander Radtke
BACKGROUND: Palmoplantar pustular psoriasis is a chronic inflammatory skin disease that is associated with considerable impairment in quality of life and resilience. Given the lack of approved pharmacological agents for this indication and the frequently recalcitrant disease course, therapeutic options are limited. PATIENTS AND METHODS: Following unsatisfactory therapeutic attempts with other treatment modalities, nine patients (six women; three men) were treated with ustekinumab (45 mg in individuals < 100 kg body weight, 90 mg in individuals > 100 kg) at weeks 0, 4, 12, and 24...
November 2016: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/27828647/generalized-pustular-psoriasis-induced-by-systemic-steroid-dose-reduction
#7
Danielle Cristine Westphal, Antonio Pedro Mendes Schettini, Petra Pereira de Souza, Jessica Castiel, Carlos Alberto Chirano, Mônica Santos
Generalized pustular psoriasis, or psoriasis of von Zumbusch, is an acute and severe clinical form of psoriasis, which usually occurs in patients with psoriasis undergoing aggravating factors. In this work, we report the case of a female patient, 70 years old, who developed generalized pustular psoriasis symptoms while reducing the dose of oral corticosteroids, improperly introduced for the treatment of alleged acute generalized exanthematous pustulosis. The differential diagnosis of generalized pustular psoriasis should be made with other pustular dermatoses, such as subcorneal pustulosis, IgA pemphigus and especially with acute generalized exanthematous pustulosis...
September 2016: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/27803422/recurrent-streptococcus-agalactiae-toxic-shock-syndrome-triggered-by-a-tumor-necrosis-factor-%C3%AE-inhibitor
#8
Masataka Yoshida, Takahiro Takazono, Masato Tashiro, Tomomi Saijo, Yoshitomo Morinaga, Kazuko Yamamoto, Shigeki Nakamura, Yoshifumi Imamura, Taiga Miyazaki, Toyomitsu Sawai, Tomoya Nishino, Koichi Izumikawa, Katsunori Yanagihara, Hiroshi Mukae, Shigeru Kohno
Streptococcal toxic shock syndrome caused by group B streptococcus (GBS) is a rare, but lethal disease. We experienced a 45-year-old woman with pustular psoriasis who developed toxic shock-like syndrome during infliximab treatment. Surprisingly, similar episodes recurred three times in one year with restarting of infliximab treatments. In the third episode, GBS were detected in blood, urine, and vaginal secretion cultures. These episodes of shock syndrome were possibly due to GBS. To the best of our knowledge, this is the first case report of recurrent streptococcal toxic shock syndrome possibly caused by GBS which was induced by anti-TNF-α inhibitor therapy...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27795221/-acute-generalized-exanthematous-pustulosis-induced-by-piroxicam
#9
Ingrid Bissinger, Gustavo Matute-Turizo, María Natalia Mejía-Barreneche
BACKGROUND: Between 62 and 90% of cases of acute generalized exanthematous pustulosis are caused by drugs. Its onset is rapid with generalized pustules, fever, and blood neutrophil count over 7000; pustules resolve spontaneously in less than 15 days. A case associated with piroxicam described. CASE REPORT: A 36-year-old with initial erythema of the thorax and abdomen, accompanied by burning, without fever, which later spread to his forearms, upper arms, and thighs, with face edema...
October 2016: Revista Alergia Mexico: Organo Oficial de la Sociedad Mexicana de Alergia e Inmunología, A.C
https://www.readbyqxmd.com/read/27783881/the-emergence-of-the-il-36-cytokine-family-as-novel-targets-for-inflammatory-diseases
#10
Patrick T Walsh, Padraic G Fallon
The recently discovered interleukin (IL)-36 family of cytokines form part of the broader IL-1 family and are emerging as important mediators of inflammatory disease. The IL-36 subfamily consists of three ligands-IL-36α, IL-36β, and IL-36γ-and the natural antagonist IL-36Ra. The cytokines exert their effects through a specific IL-36 receptor consisting of IL-36R and IL-1RAcP chains. IL-36 cytokines can direct both innate and adaptive immune responses by acting on parenchymal, stromal, and specific immune cell subsets...
October 26, 2016: Annals of the New York Academy of Sciences
https://www.readbyqxmd.com/read/27771982/systemic-cyclosporine-treatment-in-severe-childhood-psoriasis-a-retrospective-chart-review
#11
Sunil Dogra, Rahul Mahajan, Tarun Narang, Sanjeev Handa
BACKGROUND: Data regarding the use of cyclosporine (CYC) in the treatment of childhood psoriasis is meager. MATERIALS AND METHODS: The records of all psoriasis patients aged less than 18 years and treated with systemic CYC at our institute were retrieved. Clinical status of patients was assessed at regular intervals and response to therapy was graded as good (50-75% decrease in PASI) and excellent (>75% decrease). Laboratory investigations to detect CYC-induced toxicity were done at regular intervals...
October 24, 2016: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/27743912/palmoplantar-pustular-psoriasis-pppp-is-characterized-by-activation-of-the-il-17a-pathway
#12
Robert Bissonnette, Judilyn Fuentes-Duculan, Shunya Mashiko, Xuan Li, Kathleen M Bonifacio, Inna Cueto, Mayte Suárez-Fariñas, Catherine Maari, Chantal Bolduc, Simon Nigen, Marika Sarfati, James G Krueger
BACKGROUND: Palmoplantar pustular psoriasis (PPPP) is a variant of psoriasis, which has significant negative impact on quality of life. The cellular and molecular inflammatory pathways involved in PPPP have not been well studied. OBJECTIVE: Study the expression of cytokines and chemokines involved in the IL-17/IL-23 axis in palmoplantar pustular psoriasis and other difficult to treat psoriasis areas (palms, scalp, elbows and lower legs). METHODS: Skin biopsies were performed on a total of 80 patients with PPPP, non-pustular palmoplantar psoriasis (NPPPP), or psoriasis located on elbows, knees and scalp as well as 10 healthy subjects...
September 29, 2016: Journal of Dermatological Science
https://www.readbyqxmd.com/read/27743397/adalimumab-administration-after-infliximab-therapy-is-a-successful-treatment-strategy-for-generalized-pustular-psoriasis
#13
Ai Matsumoto, Mayumi Komine, Masaru Karakawa, Megumi Kishimoto, Mamitaro Ohtsuki
We report a case of a 70-year-old woman with generalized pustular psoriasis (GPP) who responded well to infliximab therapy and adalimumab therapy after secondary failure of infliximab therapy, but did not respond to ustekinumab therapy. We speculate that the pathogenic factor in this case favored anti-tumor necrosis factor (TNF)-α therapy to anti-interleukin-12/23 therapy. Herein, we also briefly present three additional cases of treatment with adalimumab after secondary failure of infliximab. GPP is often difficult to treat, and no placebo-controlled trials have been conducted to guide the use of biologics against it because of a paucity of cases...
October 15, 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/27726163/efficacy-and-safety-of-ixekizumab-treatment-for-japanese-patients-with-moderate-to-severe-plaque-psoriasis-erythrodermic-psoriasis-and-generalized-pustular-psoriasis-results-from-a-52-week-open-label-phase-3-study-uncover-j
#14
Hidehisa Saeki, Hidemi Nakagawa, Ko Nakajo, Taeko Ishii, Yoji Morisaki, Takehiro Aoki, Gregory S Cameron, Olawale O Osuntokun
Psoriasis, a chronic, immune-mediated skin disease characterized by red, scaly plaques, affects approximately 0.3% of the population in Japan. The aim of this open-label study was to evaluate the long-term efficacy and safety of ixekizumab, a humanized, anti-interleukin-17A monoclonal antibody, in Japanese patients with plaque psoriasis (n = 78, including 11 psoriatic arthritis), erythrodermic psoriasis (n = 8) and generalized pustular psoriasis (n = 5). Ixekizumab was administrated s.c. at baseline (week 0, 160 mg), from weeks 2 to 12 (80 mg every 2 weeks), and from weeks 16 to 52 (80 mg every 4 weeks)...
October 11, 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/27688451/pustular-psoriasis-occurring-on-the-striae-distensae-an-umpteenth-example-of-immunocompromised-cutaneous-district
#15
Stefano Caccavale, Tobia Caccavale, Maddalena La Montagna
No abstract text is available yet for this article.
September 2016: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/27663916/psoriasis-induced-by-anti-tumor-necrosis-factor-alpha-agents-a-comprehensive-review-of-the-literature
#16
REVIEW
Fedra Ciccarelli, Massimo De Martinis, Maria Maddalena Sirufo, Lia Ginaldi
Tumor necrosis factor alpha (TNF-α) inhibitors revolutionized the management of patients affected by autoimmune diseases such as inflammatory bowel diseases, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. The biologic agents targeted to block TNF-α such as infliximab, adalimumab, certulizumab pegol, etanercept, and golimumab, have a good safety profile; however, with increasing, broader, and prolonged use, patients could be exposed to an increased risk of adverse reactions including a wide spectrum of dermatological conditions of different etiology and morphology...
August 2016: Acta Dermatovenerologica Croatica: ADC
https://www.readbyqxmd.com/read/27617460/bullous-impetigo-and-pregnancy-case-report-and-review-of-blistering-conditions-in-pregnancy
#17
Philip R Cohen
BACKGROUND:  Bullous impetigo results from Staphylococcus aureus (S. aureus) release of exfoliative toxins type A and type B thatresults in flaccid, easily ruptured, bullae in the upper layers of the epidermis.  Physiologic, gestation-associated, and incidental skin changes can occur in pregnancy.  Blisters in pregnant women can occur secondary to either common skin disorders orspecific dermatoses of pregnancy. PURPOSE:  To describe a pregnant woman with bullous impetigo and review bullous conditions in pregnant women...
2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/27599783/identification-of-nail-features-associated-with-psoriasis-severity
#18
Jee Woong Choi, Bo Ri Kim, Eunmi Seo, Sang Woong Youn
There are no detailed studies of the prevalence of nail psoriasis and clinical characteristics of psoriatic nail involvement, including nail features associated with disease severity. Therefore, we designed a study to investigate the prevalence and characteristics of psoriatic nail involvement in patients with psoriasis and determine the relationship between psoriatic nail features and severity of nail psoriasis and cutaneous psoriasis. The Nail Psoriasis Severity Index (NAPSI) was used for evaluation of the severity of nail lesions...
September 7, 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/27577550/brodalumab-first-global-approval
#19
Sarah L Greig
Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family. Regulatory applications for brodalumab in plaque psoriasis are also under review in the USA, EU and Canada...
September 2016: Drugs
https://www.readbyqxmd.com/read/27542682/mutation-analysis-of-il36rn-gene-in-japanese-patients-with-palmoplantar-pustulosis
#20
Toshifumi Takahashi, Noriki Fujimoto, Miho Kabuto, Takeshi Nakanishi, Toshihiro Tanaka
Loss-of-function mutations of the IL36RN gene, encoding interleukin-36 receptor antagonist (IL-36Ra), have been reported as major pathogenic causes of generalized pustular psoriasis (GPP), especially in cases lacking previous histories of psoriasis vulgaris. Palmoplantar pustulosis (PPP), which is traditionally included among GPP-related diseases, has a controversial association with IL36RN. While a negative view about the said association has been recently published from Europe, variations of the IL36RN gene show great ethnic differences...
August 20, 2016: Journal of Dermatology
keyword
keyword
60193
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"